SG11202002841PA - Semaglutide in medical therapy - Google Patents
Semaglutide in medical therapyInfo
- Publication number
- SG11202002841PA SG11202002841PA SG11202002841PA SG11202002841PA SG11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA
- Authority
- SG
- Singapore
- Prior art keywords
- semaglutide
- medical therapy
- therapy
- medical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196254 | 2017-10-12 | ||
| PCT/EP2018/077654 WO2019072941A1 (en) | 2017-10-12 | 2018-10-10 | Semaglutide in medical therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002841PA true SG11202002841PA (en) | 2020-04-29 |
Family
ID=60083831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002841PA SG11202002841PA (en) | 2017-10-12 | 2018-10-10 | Semaglutide in medical therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200237876A1 (en) |
| EP (1) | EP3694538A1 (en) |
| JP (1) | JP7148605B2 (en) |
| KR (1) | KR20200069316A (en) |
| CN (1) | CN111212657A (en) |
| AU (1) | AU2018348929A1 (en) |
| BR (1) | BR112020006246A2 (en) |
| CA (1) | CA3078652A1 (en) |
| CL (1) | CL2020000812A1 (en) |
| IL (1) | IL273470A (en) |
| MA (1) | MA50358A (en) |
| MX (1) | MX2020003049A (en) |
| PH (1) | PH12020550185A1 (en) |
| SG (1) | SG11202002841PA (en) |
| TW (1) | TW201914611A (en) |
| WO (1) | WO2019072941A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4106727A1 (en) * | 2020-02-18 | 2022-12-28 | Novo Nordisk A/S | Pharmaceutical formulations |
| WO2022212271A1 (en) * | 2021-03-29 | 2022-10-06 | Sanford Health | Methods and compositions for treating lysosomal storage disorders |
| WO2023238017A1 (en) * | 2022-06-08 | 2023-12-14 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI362392B (en) * | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US9186392B2 (en) * | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| WO2013167454A1 (en) * | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| EP3689365A1 (en) * | 2012-07-01 | 2020-08-05 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| RS58039B1 (en) * | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oral dosing of glp-1 compounds |
-
2018
- 2018-10-10 SG SG11202002841PA patent/SG11202002841PA/en unknown
- 2018-10-10 KR KR1020207012311A patent/KR20200069316A/en not_active Application Discontinuation
- 2018-10-10 CA CA3078652A patent/CA3078652A1/en active Pending
- 2018-10-10 BR BR112020006246-4A patent/BR112020006246A2/en unknown
- 2018-10-10 CN CN201880066425.9A patent/CN111212657A/en active Pending
- 2018-10-10 WO PCT/EP2018/077654 patent/WO2019072941A1/en active Search and Examination
- 2018-10-10 EP EP18788709.6A patent/EP3694538A1/en active Pending
- 2018-10-10 JP JP2020517328A patent/JP7148605B2/en active Active
- 2018-10-10 AU AU2018348929A patent/AU2018348929A1/en active Pending
- 2018-10-10 MX MX2020003049A patent/MX2020003049A/en unknown
- 2018-10-10 MA MA050358A patent/MA50358A/en unknown
- 2018-10-12 TW TW107136028A patent/TW201914611A/en unknown
-
2020
- 2020-03-20 IL IL273470A patent/IL273470A/en unknown
- 2020-03-27 PH PH12020550185A patent/PH12020550185A1/en unknown
- 2020-03-27 CL CL2020000812A patent/CL2020000812A1/en unknown
- 2020-04-09 US US16/844,552 patent/US20200237876A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200237876A1 (en) | 2020-07-30 |
| MA50358A (en) | 2020-08-19 |
| CL2020000812A1 (en) | 2020-08-14 |
| MX2020003049A (en) | 2020-07-27 |
| IL273470A (en) | 2020-05-31 |
| CN111212657A (en) | 2020-05-29 |
| JP2022132414A (en) | 2022-09-08 |
| PH12020550185A1 (en) | 2021-03-01 |
| BR112020006246A2 (en) | 2021-03-30 |
| AU2018348929A1 (en) | 2020-05-07 |
| WO2019072941A1 (en) | 2019-04-18 |
| TW201914611A (en) | 2019-04-16 |
| JP2020536854A (en) | 2020-12-17 |
| KR20200069316A (en) | 2020-06-16 |
| RU2020114960A (en) | 2021-10-28 |
| CA3078652A1 (en) | 2019-04-18 |
| EP3694538A1 (en) | 2020-08-19 |
| RU2020114960A3 (en) | 2022-02-11 |
| JP7148605B2 (en) | 2022-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260383B (en) | Low dose therapeutic treatment | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| EP3723685C0 (en) | Medical dressing | |
| IL268305B1 (en) | Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced | |
| IL260771B1 (en) | Catheter locking solution and catheter locking therapy | |
| SG11201707816PA (en) | Patient interface and aspects thereof | |
| HK1253237A1 (en) | 3d human body correction apparatus | |
| IL250990A0 (en) | Human therapeutic agents | |
| SG10202010420TA (en) | Patient interface and aspects thereof | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| GB201604213D0 (en) | Drug combination and its use in therapy | |
| IL290251A (en) | Combination for the effective treatment of metastatic cancer in patients | |
| PL3253208T3 (en) | Combination therapies for use in the treatment of breast cancer | |
| IL247969B (en) | A therapeutic agent for use in the treatment of infections | |
| IL273470A (en) | Semaglutide in medical therapy | |
| GB201709840D0 (en) | Methods and medical uses | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| EP3723686C0 (en) | Medical dressing | |
| GB201513097D0 (en) | Medical implant | |
| PT3325478T (en) | New therapeutic compound and use in therapy | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| GB201607594D0 (en) | Patient stimulation device | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| EP3727136C0 (en) | Implantable medical device | |
| IL268265B (en) | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment |